BRAF and non-small cell lung carcinoma: Non-small-cell lung cancer (NSCLC) cell lines bearing EGFR, KRAS, BRAF, ALK or RET mutations were found with high level of PD-L1 expression, and this may be correlated with high levels of PI3K/AKT/mTOR pathway activation.